MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells

Amirhosein Maharati1, Amir Sadra Zanguei1, Ghazaleh Khalili-Tanha2 and Meysam Moghbeli2*

Abstract
Lung cancer is the second most common and the leading cause of cancer-related deaths globally. Tyrosine Kinase Inhibitors (TKIs) are among the common therapeutic strategies in lung cancer patients, however the treatment process fails in a wide range of patients due to TKIs resistance. Given that the use of anti-cancer drugs can always have side effects on normal tissues, predicting the TKI responses can provide an efficient therapeutic strategy. Therefore, it is required to clarify the molecular mechanisms of TKIs resistance in lung cancer patients. MicroRNAs (miRNAs) are involved in regulation of various pathophysiological cellular processes. In the present review, we discussed the miRNAs that have been associated with TKIs responses in lung cancer. MiRNAs mainly exert their role on TKIs response through regulation of Tyrosine Kinase Receptors (TKRs) and downstream signaling pathways. This review paves the way for introducing a panel of miRNAs for the prediction of TKIs responses in lung cancer patients.

Keywords: Non-small cell lung cancer (NSCLC), Tyrosine kinase inhibitor (TKI), Resistance, MicroRNA (miRNA), Diagnosis, Prognosis

Background
Lung cancer is the leading cause of cancer-related mortality and the third most common cancer worldwide [1]. Lung cancers are classified into two broad categories based on histopathological features: Non-Small-Cell Lung Cancer (NSCLC) and Small-Cell Lung Cancer (SCLC). NSCLC accounts for almost 85% of newly diagnosed lung cancer cases and has three main subclasses: adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma [2]. While tremendous progress has been achieved in the last decade, the prognosis for lung cancer remains poor, with just 19% of patients survive for longer than five years. A substantial proportion of NSCLC patients have genetic alterations in Epidermal Growth Factor Receptor (EGFR) that activate it constitutively [3–6]. Tyrosine kinases are categorized into the trans-membrane Receptor Tyrosine Kinases (RTKs) and cytoplasmic Non-Receptor Tyrosine Kinases (NRTKs) [7]. RTKs are involved in both extracellular and intracellular signaling pathways. They often serve as binding sites for cytoplasmic molecules that activate downstream pathways. RTK ligand binding triggers receptor dimerization and auto-phosphorylation that results in activation of downstream signaling molecules involved in cell proliferation and tumor progression [8]. EGFR is a transmembrane glycoprotein belonging to the Receptor Tyrosine Kinases (RTKs) family that activates Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinositol 3-Kinase (PI3K)/protein kinase B (AKT), and Janus Kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) signaling pathways to regulate cell proliferation and angiogenesis [9–11]. EGFR deregulations are found in various cancers [12,

*Correspondence: Meysam_moghbeli@yahoo.com; moghbelim@mums.ac.ir
2 Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
NRTKs usually have interaction with transmembrane receptors and transduce extracellular signals. They have also a critical role in regulation of cell proliferation, apoptosis, and immune response through PI3K/AKT and MAPK signaling pathways [14, 15]. Targeting the EGFR is authorized as a first-line treatment option for NSCLC patients with an activating EGFR mutation and a second-line in patients with advanced NSCLC [16–19]. EGFR-Tyrosine Kinase Inhibitors (TKIs) inhibit EGFR phosphorylation and thus interfere with MEK-ERK, PI3K-AKT, and JAK-STAT activation. For locally developed or metastatic NSCLC with mutant EGFR, oral administration of EGFR-TKIs such as Gefitinib, Erlotinib, Afatinib, and Osimertinib are the conventional treatment options [20, 21]. Nevertheless, specific NSCLC patients who carry EGFR-TKI-sensitizing mutations do not respond to EGFR-TKIs. Resistance to EGFR-TKIs develops in approximately one year that severely reduces the long-term efficiency [22, 23]. MicroRNAs (miRNAs) are non-coding RNAs that regulate gene expression through translational repression and mRNA cleavage [24]. MiRNAs functions as oncogenes or tumor suppressor genes in regulating cell proliferation and apoptosis [25, 26]. They regulate cancer cell susceptibility to chemotherapy and prevent tumor cell motility and invasion [27–30]. They can also down-regulate the EGFR signaling transduction while restoring Gefitinib cytotoxicity in NSCLC cells [31]. Although, TKIs are effective therapeutic modalities in the targeted therapy of various cancers, they cause various adverse effects on skin and hair, anemia, hypothyroidism, and diarrhea [32]. Therefore, it is required to detect the lung cancer patients who are resistant toward the TKIs to manage the therapeutic methods and reduce side effects. Since, the miRNAs are stable in body fluids; they can be used as the non-invasive diagnostic and prognostic markers [33, 34]. Therefore, in the present review we have discussed the miRNAs involved in regulation of TKIs response in lung cancer (Fig. 1) (Table 1).

![Molecular mechanisms of microRNAs involved in regulation of TKIs responses in lung tumor cells. All of the microRNAs that targeted the RTKs were involved in increased TKIs sensitivity in lung tumor cells. MiR-214, miR-21, and miR-23a promoted TKIs resistance through PTEN targeting. SNHG14 and LINC0060 also increased TKIs resistance by miR-206-3p and miR-149-5p targeting and following ABCB1 and IL-6 up regulations in lung tumor cells. MiR-3127-5p and miR-146b-5p were also involved in increased TKIs sensitivity through ABL and IRAK1 targeting, respectively. (Created with BioRender.com)](image-url)
Table 1 All of the microRNAs associated with TKIs response in lung tumor cells

| Gene       | Samples                                      | Results                                                                 | Animal study                      | References |
|------------|----------------------------------------------|------------------------------------------------------------------------|-----------------------------------|------------|
| miR-1      | 21 tumor tissues, 21 resistant tumor tissue, PC9 and H1975 cell lines | Inhibited monocytes and lymphocyte motility by cytokines down regulations and reduced intra-tumoral CD8-positive T cells | –                                 | Kawana [60]|
| miR-1-3p   | HCC827 and PC9 cell lines, Xenograft model   | Overcome HGF-induced Gefitinib resistance in EGFR mutant lung cancer cells by AKT/ERK inhibition  | MiR-1-3p reversed HGF-induced resistance to Gefitinib in vivo | Jiao [59] |
| miR-7      | PC-9RPC-9, H3255, A549 and H1975 cell lines, Xenograft model | Overcomes acquired resistance to EGFR-TKI produced by secondary mutations in EGFR-addicted cancers | MiR-7 reversed resistance to EGFR-TKI in vivo | Rai [52]  |
| miR-7      | A549 cell line                               | Increased the gefitinib sensitivity through inhibition of IGF1R/Pi3K/Akt and EGFR/Raf1/ERK signaling pathways in NSCLC cells | –                                 | Zhao [53]  |
| miR-19a    | 15 serum samples, HCC827, H1975, A549, and PC9 cell lines, Xenograft model | Promoted Gefitinib sensitivity by c-Met targeting in NSCLC cells       | MiR-19a decreased Gefitinib resistance in xenograft model | Cao [83]  |
| miR-30a-5p | H1650, H460, and H1975 cell lines, Xenograft model | Inhibited the PI3K/AKT signaling pathway                               | MiR-30a-5p increased Gefitinib sensitivity in vivo | Wang [51] |
| miR-128    | PC9 cell line, Xenograft model               | Reversed Gefitinib resistance by reducing the CSC population by inhibiting c-met/Pi3K/AKT axis | MiR-128 increased the anti-tumor effect of Gefitinib on NSCLC in xenograft model | Jiang [70]|
| miR-130a   | A549, H1975, and PC9 cell lines              | Promoted Gefitinib sensitivity in NSCLC cells by Met targeting         | –                                 | Zhou [58]  |
| miR-133b   | 32 tumor tissue, A549 and H1299 cell lines   | Was associated with Erlotinib effectiveness                              | –                                 | Bisagni [54]|
| miR-138-5p | 20 normal and tumor tissues, PC9 and H1975 cell lines | Inhibited angiogenesis by GPR124 down regulation                      | –                                 | Gao [82]  |
| miR-149-5p | A549, H1299, H1975 and, PC9 cell lines      | LINCO0460 sponged miR-149-5p to up regulate IL6 in lung cancer cells   | –                                 | Nakano [129]|
| miR-200a   | H3255, H1975, and HCC827 cell lines         | Inhibited NSCLC cells' migration and invasion, while increased Gefitinib sensitivity | –                                 | Zhen [31] |
| miR-200c   | 150 tumor tissues, PC9, H23, A549, H1975, H460 and H1299 cell lines | Increased Gefitinib sensitivity via ZEB1 targeting                     | –                                 | Li [110]  |
| miR-200c   | PC9 cell line, Xenograft model               | Increased sensitivity to Gefitinib via inhibiting the PI3K/AKT signaling pathway and cell migration by ZEB1 targeting | MiR-200c enhanced sensitivity of tumor cells to Gefitinib and induced apoptosis in xenograft model | Zhou [111]|
| miR-206    | 37 tumor and 14 normal tissues, PC9 and HCC827 cell lines | Increased Gefitinib sensitivity by blocking the IL6/JAK1/STAT3 pathway in IL6-induced lung cancer resistance cells | –                                 | Yang [127]|
| miR-206    | HCC827 and PC9 cell lines, Xenograft model   | Overcome HGF-induced Gefitinib resistance in EGFR mutant lung cancer cells by AKT/ERK inhibition | MiR-1-3p reversed HGF-induced resistance to Gefitinib in vivo | Jiao [59] |
| miR-206-3p | 36 Gefitinib-resistant (GR) and 42 Gefitinib-sensitive (GS) tissues, PC9 cell line, Xenograft model | SNHG14 increased ABCB1 protein expression by miR-206-3p sponging, leading to NSCLC Gefitinib resistance | Silencing of SNHG14 increased sensitivity to Gefitinib in vivo | Wu [169]  |
Table 1 (continued)

| Gene         | Samples                                      | Results                                                                 | Animal study                                      | References |
|--------------|----------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------|------------|
| miR-223      | • PC9 cell line                             | Promoted apoptosis in tumor cells by targeting the IGF1R/AKT/P65 signaling pathway and increased Erlotinib sensitivity | Combination of miR-223 and Erlotinib increased sensitivity of tumor cells | Zhao [73]  |
|              | • Xenograft model                           |                                                                         |                                                  |            |
| miR-223      | • PC9 cell line                             | Inhibited the IGF1R/P13K/AKT signaling pathway and Erlotinib resistance | MiR-223 reversed resistance to Erlotinib in vivo  | Han [157]  |
| miR-365a-5p  | • 27 normal and 58 tumor tissues            | Reduced cell proliferation and Gefitinib resistance via PEL1S targeting | MiR-365a-5p significantly decreased the tumor size in xenograft model | Li [99]    |
|              | • PC9 cell line                             |                                                                         |                                                  |            |
|              | • Xenograft model                           |                                                                         |                                                  |            |
| miR-483-3p   | • HCC827, H1975, A549, H292, H1299, and PC9 cell lines | Promoted Gefitinib sensitivity in NSCLC by decreasing resistant cell growth, inducing apoptosis, inhibition of invasion and migration | Silencing of miR-483-3p promoted Gefitinib resistance in EGFR-mutant NSCLC | Yue [114]  |
|              | • Xenograft model                           |                                                                         |                                                  |            |
| miR-497      | • A549 and A549/GR cell lines               | Reduced IGF-1R expression and inhibited AKT1 signaling in NSCLC cells   |                                                  | Ma [72]    |
|              | • Xenograft model                           |                                                                         |                                                  |            |
| miR-506-3p   | • HCC4006 cell line                         | Under expression of miR-506 activated the SHH pathway and induced EGFR-TKI resistance |                                                  | Haque [172]|
| miR-506-3p   | • 25 normal and tumor tissues               | Gefitinib resistance via YAP1 regulation in NSCLC cells                |                                                  | Zhu [214]  |
| miR-608      | • 319 tumor tissues                        | Was prognostic indicator for lung cancer during Gefitinib treatment     |                                                  | Zhang [75] |
|              | • PC9 cell line                             |                                                                         |                                                  |            |
| miR-630      | • 46 tumor tissues                          | MiR-630 down regulation promoted ERK activation through YAP1 up regulation that resulted in TKI resistance |                                                  | Wu [215]   |
|              | • PC9 and CL97 cell lines                   |                                                                         |                                                  |            |
| miR-873      | • PC9 cell line                             | MiR-873 suppression significantly promoted the proliferation of Gefitinib-treated PC9 cells, followed by GLI1 up regulation |                                                  | Jin [175]  |
| miR-1262     | • 46 normal and tumor tissues               | MiR-1262 rs12740674 T allele was correlated with poor prognosis        |                                                  | Lei [74]   |
| miR-3127-5p  | • 177 normal and tumor tissues              | Inhibited tumor cell growth and invasion by c-Abl targeting            | miR-3127-5p decreased NSCLC tumorigenicity and metastasis in xenograft model | Sun [105]  |
|              | • A549 and H292 cell lines                  |                                                                         |                                                  |            |
|              | • Xenograft model                           |                                                                         |                                                  |            |
| miR-4513     | • 319 tumor tissues                         | miR-4513 was prognostic indicator for lung cancer during Gefitinib treatment |                                                  | Zhang [75] |
|              | • H1299 and PC9 cell lines                  |                                                                         |                                                  |            |
| Increasing resistance to TKIs |                              |                                                                         |                                                  |            |
| miR-21       | • 25 plasma samples before treatment        | Inhibited PTEN and PDCD4 expression, while induced P13K/AKT pathway    | Suppression of miR-21 inhibited tumor progression in vivo | Li [143]   |
|              | • 25 plasma samples after treatment         |                                                                         |                                                  |            |
|              | • PC9 cell line                             |                                                                         |                                                  |            |
|              | • Xenograft model                           |                                                                         |                                                  |            |
| miR-23a      | • PC9 cell line                             | miR-23a down regulation increased Erlotinib sensitivity of CSCs through PTEN up regulation |                                                  | Han [144]  |
| Gene     | Samples                              | Results                                                                 | Animal study                                              | References |
|----------|--------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------|------------|
| miR-26a  | • 5 tumor tissues                    | Promoted cell growth and TKI resistance via PTPN13 targeting            | miR-26a increased Gefitinib resistance in vivo            | Xu [156]   |
|          | • A549, H520, SW900, H2170, and PC-9 cell lines |                                                                          |                                                           |            |
|          | • Xenograft model                    |                                                                          |                                                           |            |
| miR-30b  | 29 plasma samples before treatment   | Elevated plasma levels were associated with Erlotinib’s inadequate response in EGFR mutant NSCLC patients | –                                                         | Hojbjerg [152] |
|          | 29 plasma samples after treatment    |                                                                          |                                                           |            |
| miR-30c  | 29 plasma samples before treatment   | Elevated plasma levels were associated with Erlotinib’s inadequate response in EGFR mutant NSCLC patients | –                                                         | Hojbjerg [152] |
|          | 29 plasma samples after treatment    |                                                                          |                                                           |            |
| miR-135  | • A549, H1650, H1975, H157, and H4006 cell lines | MiR-135 suppression down regulated Bcl-2 while up regulated Bax that resulted in increased apoptosis | –                                                         | Wang [130] |
| miR-135a | • NCH1650 and                         | Stimulated cell proliferation, invasion, and Gefitinib resistance in NSCLC cells through RAC1 targeting | –                                                         | Zhang [160] |
|          | • NCH1979 cell lines                 |                                                                          |                                                           |            |
| miR-200c | • HCC4006 cell line                  | MiR-200c/LIN28B axis plays an essential role in acquired EGFR-TKI resistance | –                                                         | Sato [113] |
| miR-214  | • 7 EGFR mutant tumor tissues        | Promoted Erlotinib resistance through LHX6 targeting                    | –                                                         | Liao [191] |
|          | • HCC827 cell line                   |                                                                          |                                                           |            |
| miR-214  | • HCC827 cell line                   | Gefitinib resistance in EGFR mutant cell lines was achieved through interplay with the PTEN/AKT signaling pathway | –                                                         | Wang [142] |
| miR-223  | • HCC827 cell line                   | Inhibited the IGFIR/PI3K/AKT signaling pathway and Erlotinib resistance  | miR-223 reversed the resistance to Erlotinib in xenograft model | Han [157] |
|          | • Xenograft model                    |                                                                          |                                                           |            |
| miR-223  | • HCC827 cell line                   | Promoted the AKT and Notch signaling pathways and modulated NSCLC cell susceptibility to Erlotinib by regulating FBXW7 | –                                                         | Zhang [224] |
| miR-299-3p| • 44 sensitive tumor tissues         | RHPN1-AS1 regulated Gefitinib resistance in NSCLC by miR-299 targeting  | Combination of RHPN1-AS1 and Gefitinib inhibited tumor growth in vivo | Li [205]   |
|          | • 40 resistant tumor tissues         |                                                                          |                                                           |            |
|          | • A549, H1975, H1299, H1070, H1251, H4006 cell lines |                                                                          |                                                           |            |
|          | • Xenograft model                    |                                                                          |                                                           |            |
| miR-451  | • A549 and H1975 cell lines          | NOTCH-1 promoted Gefitinib resistance in LUAD cells through SNHG15/miR-451/ZEB1 axis in vivo and in vitro | SNHG15/miR-451/ZEB1 axis induced Gefitinib resistance in xenograft model | Huang [223] |
|          | • Xenograft model                    |                                                                          |                                                           |            |
| miR-641  | • 18 T tissues                       | Promoted Erlotinib resistance in NSCLC cells by NF1 targeting           | Combination of miR-641 and Erlotinib increased apoptosis and decreased tumor cells proliferation in vivo | Chen [84]  |
|          | • 18 resistant T tissues             |                                                                          |                                                           |            |
|          | • PC9 cell line                      |                                                                          |                                                           |            |
|          | • Xenograft model                    |                                                                          |                                                           |            |
| miR-762  | • 59 tumor tissues                   | Gefitinib resistance in NSCLC cells by mediating the IL6/STAT3 pathway   | miR-762 promoted Gefitinib resistance and increased tumor formation in a xenograft model | Ge [128]   |
|          | • A549, NCI-H820, NCI-H2170, NCI-H1650, NCI-H1993, NCI-H2165, NCI-H1975, NCI-H1299, NCI-H1648, NCI-H1703, NCI-H2347 and PC9 cell lines |                                                                          |                                                           |            |
|          | • Xenograft model                    |                                                                          |                                                           |            |
Receptor tyrosine kinases (RTKs)

RTKs are trans-membrane proteins that are expressed on different cell types and are implicated in a myriad of cellular mechanisms including proliferation, cell survival, and cell–cell communication [35]. Deregulation of RTKs leads to the development of different diseases, most particularly, malignancies as it is reported that approximately 30% of RTKs are mutated or aberrantly expressed in different human cancers [36]. EGFR is a trans-membrane glycoprotein with an intracellular tyrosine kinase domain that is autophosphorylated to activate MAPK and PI3K pathways [3, 37–40]. EGF triggers the tyrosine kinase activity of EGFR that regulates cell proliferation, migration, and apoptosis [41]. There is EGFR up regulation in about 60% of NSCLC patients [42]. In NSCLC patients with activating EGFR mutations, EGFR tyrosine kinase inhibitors (EGFR-TKI) have a remarkable impact and prolonged survival compared with standard treatments [43–45]. Gefitinib as an EGFR-TKI has been authorized for patients with EGFR mutations in exon 19 (deletions) or exon 21 (Leu858Arg) [46, 47]. Compared with platinum-based combination chemotherapy, Gefitinib delays tumor progression and enhances overall survival. Nevertheless, many individuals develop resistance to TKIs throughout treatment [40, 48, 49]. Due to an EGFR T790M mutation in exon 20, around 50% of patients who initially responded to EGFR-TKI developed resistance to EGFR-TKI [50]. EGFR and IGF1R suppression can inhibit the PI3K/AKT signaling pathway. It has been shown that Gefitinib and miR-30a-5p mimics reduced EGFR-TKIs resistance [51]. The delivery of miR-7 plasmids through cationic liposomes may be exploited to overcome acquired resistance to EGFR-TKI produced by secondary EGFR mutations [52]. MiR-7 increased the Gefitinib sensitivity through suppression of IGF1R and EGFR signaling pathways in NSCLC cells [53]. It has been shown that up regulation of miR-133b and miR-146a while miR-7 down regulation was associated with Erlotinib effectiveness in NSCLC. Since, there was a correlation between miR-133b up-regulation and prolonged Progression-Free Survival (PFS) in NSCLC patients taking Erlotinib, it is postulated that miR-133b might improve Erlotinib sensitivity. MiR-200c also increased Gefitinib sensitivity [54]. APCDD1L-AS1 promoted Icotinib resistance through miR-1322/miR-1972/miR-324-3p sponging that up regulated the SIRT5 and EGFR in lung tumor cells. SIRT5 inhibited the EGFR autophagic degradation to induce Icotinib resistance [55].

Met is a RTK that can be activated by Hepatocyte Growth Factor (HGF) to promote the MAPK and PI3K/AKT downstream pathways. It is involved in EGFR-TKI resistance of NSCLC patients [56, 57]. There was miR-130a up regulation in Gefitinib-sensitive NSCLC cells that promoted Gefitinib sensitivity in NSCLC cells by Met targeting [58]. MiR-1-3p and miR-206 may also overcome HGF-induced Gefitinib resistance via suppression of c-Met signaling in EGFR mutant lung cancer cells [59]. Tumor Immune Microenvironment (TIME) alterations have been examined before and after the development of EGFR-TKI resistance. It has been found that miR-1 increased EGFR-TKI sensitivity by reduction of the CD8+ T cells migration. MiR-1 inhibited monocytes and lymphocytes motility by cytokines down regulations. MiR-1 reduced intratumoral CD8+ T cells in EGFR-TKI resistant lung cancer patients [60]. EGFR has also been shown to interact with the c-Met regularly [61, 62]. It has been shown that miR-200a reduced cell invasion and Gefitinib resistance in NSCLC cells through EGFR and c-Met down regulations [31]. There were also significant reduced serum miR-19a levels in Gefitinib resistant patients. MiR-19a down regulation promoted Gefitinib resistance and Epithelial-to-Mesenchymal Transition (EMT) in Gefitinib-sensitive NSCLC cells. MiR-19a promoted Gefitinib sensitivity by c-Met targeting in NSCLC cells [63]. Cancer Stem Cells (CSCs) are a group of tumor cells involved in chemo resistance [64]. Since, CSCs can differentiate and cause diverse cell populations to form tumor bulks, they are considered as the main tumor-initiating cells [65]. CD133+ populations of NSCLC-CSCs are responsible for increased chemotherapeutic resistance and tumor relapse [66, 67]. HGF/c-Met signaling induced tumor progression through PI3K/AKT pathway [68, 69]. There was miR-128 down regulation in PC9-CSCs. MiR-128 reversed Gefitinib resistance via c-Met/PI3K/AKT inhibition and reducing the CSC population [70].

Insulin-like Growth Factor-1 Receptor (IGF1R) belongs to RTKs protein family that can be activated by autophosphorylation in conjunction with the Insulin-like Growth Factors (IGFs) to promote MAPK and PI3K/AKT signaling pathways. Therefore, IGF1R can control cell proliferation, differentiation, metabolism, and apoptosis [71]. It is hypothesized that aberrant IGF1R activation may increase the PI3K/AKT signaling pathway, thus conferring resistance to EGFR-TKIs. It has been shown that miR-497 can also regulate NSCLC’s resistance to Gefitinib. MiR-497 reduced IGF1R expression and inhibited AKT1 signaling in NSCLC cells. MiR-497 may influence tumor cell responsiveness to chemotherapy and tumor cell resistance to EGFR-TKI via IGF1R targeting and AKT activation [72]. It has also been reported that miR-223 promoted apoptosis in tumor cells by targeting the IGF1R/Akt/S6 signaling pathway and increased Erlotinib sensitivity [73].

The prognostic impact of the miR-1262 rs12740674 variation has been investigated in advanced lung cancer
patients treated by EGFR-TKIs. The rs12740674 T allele was correlated with a worse prognosis. The miR-1262 rs12740674 T allele was substantially related to poor prognosis following EGFR-TKI treatment. MiR-1262 also significantly increased the susceptibility of lung adenocarcinoma cells to Gefitinib [74]. MiR-4513 rs2168514 and miR-608 rs4919510 polymorphisms were also substantially correlated with the prognosis of lung cancer patients treated with Gefitinib. Carriers of homozygous CC variant of rs4919510 had significantly longer OS and PFS than those with the GG variant. The carriers of heterozygous GA variant of rs2168518 had also a better prognosis in comparison with the GG variant. The rs4919510 and rs2168518 polymorphisms were prognostic indicators for lung cancer during Gefitinib treatment [75].

G-protein Coupled Receptor 56 (GPR56) has a pivotal role in cell adhesion and angiogenesis [76]. GPR124 functions as an angiogenesis regulator, and abnormal tumor angiogenesis have been associated with anti-EGFR therapeutic resistance [77–81]. Gefitinib-resistant cell lines were sensitized to Gefitinib using miR-138-5p. Gefitinib resistance was associated with miR-138-5p down regulation. Elevated amounts of miRNA-138-5p down-regulated GPR124 in PC9 cells, and this modulation contributed to drug sensitivity [82].

**MEK/ERK and JAK/STAT signaling pathways**

The Mitogen-Activated Protein Kinase (MAPK) pathway regulates diverse cellular mechanisms including proliferation, differentiation, and motility [83]. MAPK pathway is activated by kinase cascades. Consecutive activation of the MAPK Kinase Kinase (MAPKKK) and MAPK Kinase (MAPKK) promote a specific MAPK which then phosphorylates different proteins in the cytosol and nucleus to exert its biological impacts through alterations in protein function and gene transcription [84]. Three main subfamilies of MAPKs include ERK, JNK, and p38 [85]. Compromised MAPK signaling has been correlated with diabetes, cancers, and neurodegenerative disorders [86, 87]. Increased p38-MAPK pathway activity was demonstrated to be associated with higher MDR1 expression and multidrug resistance in tumor cells [88]. The MEK/ERK pathway is a crucial downstream signaling cascade required for cell growth and neoplastic transformation. As a result, MEK inhibitors have been intensively explored to treat different solid tumors in clinical trials [89, 90]. MEK-inhibitors have clinical responses in some patients, however a minority of tumors are resistant [91, 92]. It has been reported that up-regulation of miR-17-92 via activation of the STAT3 pathway caused MEK inhibitor resistance. Concurrent suppression of the MEK and STAT or miR-17 sensitized resistant cells to AZD6244 treatment substantially via Bcl-2 Interacting Protein (BIM) up-regulating [93]. Neurofibromin 1 (NF1) is a GTPase-activating protein that inhibits the Ras signaling pathway, which, in turn, inhibits the MAP-ERK kinase MiR-641 up-regulation in EGFR-TKI-resistant NSCLC cells promoted Erlotinib resistance in NSCLC cells by directly targeting NFI via activation of ERK signaling. MiR-641 may also render EGFR-TKI-resistant NSCLC cells susceptible to TKI therapy [94]. PELI3 is a scaffolding protein that promotes the ETS Like-1 protein (Elk-1) and c-Jun signaling pathways and regulates innate immune responses [95, 96]. PELI3 is an E3 ubiquitin protein ligase with a function in insulin resistance and inflammation [97]. Elk1 needs to be phosphorylated by MAPKs to activate the FOS proto-oncogene [98]. There was PELI3 up-regulation in NSCLC cell lines and tissues which was associated with a poor prognosis. MiR-365a-5p reduced cell proliferation and Gefitinib resistance via Pellino E3 Ubiquitin Protein Ligase Family Member 3 (PEL13) targeting [99].

Abelson Tyrosine-Protein Kinase 1 (ABL1) is a cytoplasmic and nuclear tyrosine kinase involved in cell proliferation, adhesion, and stress response [100]. The c-Abl promotes cell proliferation and tumorigenesis in various cancers [101–103]. Activated c-Abl also phosphorylates the EGFR that is resulting in reduced EGFR internalization and increased EGFR expression. The c-Abl directly interacts with the Grb2 to activate Ras/ERK pathway [104]. There was significant miR-3127-5p down regulation in recurrent NSCLC tumor tissue compared with initial tumors. MiR-3127-5p expression was significantly correlated with advanced tumor stage in NSCLC. MiR-3127-5p significantly reduced tumor cell growth and invasion by targeting the c-Abl and regulating the c-Abl/Ras/ERK pathway. Dasatinib sensitivity was also associated with miR-3127-5p down regulation in NSCLC cells [105].

EMT is characterized by Cadherin 1 (CDH1) down-regulation and up regulation of the mesenchymal biomarkers. EMT increases tumor cell motility, invasion, and drug resistance. Acquiring the mesenchymal phenotype is linked with chemo resistance and confers primary resistance to Trastuzumab, a HER2/neu inhibitor [106, 107]. EMT has been related to resistance to EGFR-TKIs in NSCLC patients. Mesenchymal markers are also expressed in clinical samples with EGFR-TKI resistance [108, 109]. Zinc finger E-box-binding homeobox (ZEB) family proteins as the CDH1 transcriptional repressors are pivotal targets in the miRNA-mediated EMT process. It has been shown that miR-200c regulated EMT and increased Gefitinib sensitivity via ZEB1 targeting in NSCLC cells. Patients with miR-200c up-regulation may benefit more from EGFR-TKIs compared with miR-200c down-regulation. MiR-200c inhibited MEK/ERK pathway
to re-sensitize Gefitinib resistant NSCLC cells [110]. MiR-200c increased drug-resistant PC9-ZD sensitivity to Gefitinib via ZEB1 targeting [111]. LIN28B and LIN28A are RNA-binding proteins that have many biological roles. LIN28 family reprograms the somatic cells to pluripotent stem cells in combination with self-renewal transcription factors [112]. The miR-200c/LIN28B axis is required to maintain EGFR-TKI resistance cells with EMT features. This axis has an essential role in EGFR-TKI resistance [113]. There was significant miR-483-3p down regulation in Gefitinib-resistant NSCLC cells and lung tissues. MiR-483-3p promoted Gefitinib sensitivity in NSCLC by decreasing resistant cell growth and inducing apoptosis. It also decreased EMT phenotype and metastasis in Gefitinib-resistant NSCLC cells. Moreover, miR-483-3p down regulation activated the FAK/ERK pathway through up-regulating integrin β3. The miR-483-3p suppression in Gefitinib-resistance cells was related to promoter hyper methylation [114].

The JAK/STAT signaling pathway is implicated in multiple pathophysiological mechanisms such as cell proliferation, differentiation, immunity, cytokine functions, and tumorigenesis [115, 116]. Following the interaction of cytokines with the receptor, JAKs phosphorylate the STATs to form a dimer that translocates into the nucleus to induce the transcription of target genes [117]. Higher STAT3 activation is associated with increased risk of recurrence and shorter survival in different cancers [118]. JAK/STAT pathway also leads to the failure of conventional chemotherapy via promoting the expression of EMT-inducing transcription factors [119]. STAT3 is an oncogenic transcription factor regularly activated in cancer and tumor-related myeloid cells by the IL-6 [120]. IL6-induced STAT3 deregulation is associated with tumor progression in various cancers [121–123]. IL6/STAT3 signaling may result in drug resistance [124–126]. EGFR mutant lung cancer cells evade Gefitinib therapy by over-activating STAT3 via miR-206 down regulation [127]. ABR regulates various biological activities by inhibiting the small GTPase Rac activity. ABR dysfunction is associated with IL-6 activation. Hypoxia stimulates the GTP-bound form of Rac, resulting in increased IL-6 production during the pathogenesis of pulmonary hypertension. There was significant miR-762 up regulation in Gefitinib-resistant NSCLC cells compared to parental cells. Increased expression of miR-762, which is mediated by the IL6/STAT3 signaling pathway, resulted in Gefitinib resistance in NSCLC cells [128]. LINCO00460 is a competitive endogenous RNA decoy for the miR-149-5p that consequently boosts IL-6 production and EMT-like characteristics in lung cancer cells. Patients with a high LINCO00460 expression had a substantially lower PFS and OS after Gefitinib treatment [129]. It has been reported that miR-135 promoted Gefitinib resistance in NSCLC cells. MiR-135 down-regulated CDH1 and b-catenin while up-regulated PD-L1. MiR-135 inhibition affected the NSCLC cells by TRIM16 up-regulation. JAK/STAT signaling pathway was also implicated in miR-135 and TRIM16 regulation. MiR-135 suppression down-regulated Bcl-2 while up-regulated Bax that increased apoptosis [130].

PI3K/AKT signaling pathway

PI3K/AKT pathway is an intracellular signal transduction pathway that plays a crucial role in regulating cellular metabolism, proliferation, growth, and angiogenesis in response to extracellular signals [131, 132]. Following activation of PI3K by growth factors [133, 134], AKT is phosphorylated, activated, and localized in the plasma membrane and can exert different downstream effects such as CREB and mTOR activation, p27 inhibition, and FOXO localization in the cytoplasm [134–136]. The abnormal PI3K/AKT activation in cancer cells promotes the expression of ATP-Binding Cassette (ABC) transporters, inhibits apoptosis, and induces tumor growth, thereby contributing to the reduced response to chemotherapeutic medications [137]. EGFR-TKIs might reduce EGFR downstream pathway activity, primarily through the PI3K/AKT pathway, which inhibits cell proliferation, invasion, and induction of apoptosis [138]. Phosphatase and Tensin Homolog (PTEN) as a suppressor of PI3K/AKT pathway is associated with EGFR-TKIs resistance [139, 140]. PTEN is a tumor suppressor protein that converts PIP3 to PIP2 to inhibit the PI3K/AKT pathway [141]. There was a significant up-regulation of miR-214 in HCC827/GR. MiR-214 regulated the PTEN/AKT signaling pathway in NSCLC EGFR mutant cells. The potential of miR-214 to modulate acquired resistance to Gefitinib in EGFR mutant cell lines was achieved through interplay with the PTEN/AKT signaling pathway [142]. There was miR-21 up regulation in advanced EGFR-TKI resistant NSCLC patients. MiR-21 promoted EGFR-TKI resistance via PTEN and PDCD4 targeting that resulted in PI3/AKT induction [143]. There was significant miR-23a up-regulation in CD133 positive PC9 CSCs. Inhibition of miR-23a increased Erlotinib sensitivity of CSCs through PTEN up regulation [144].

IGF1R is involved in neoplastic transformation and drug resistance of a wide variety of tumors [145, 146]. The PI3K/AKT pathway as one of the common EGFR downstream signaling pathways are activated by IGF1R [147]. IGF1R activity is related to EGFR-TKI resistance in NSCLC cell lines and lung cancer patients [148, 149]. IGF1R-TKI can overcome EGFR-TKI resistance in vitro and in vivo [147, 150]. It has been shown that miR-30a-5p down regulated PIK3R2, hence lowering the amount of
p-AKT in cell lines. *MiR-30a-5p* inhibited cell migration while promoted apoptosis by PIK3R2 targeting. Therefore, *miR-30a-5p* in combination with other EGFR-TKI agents increased tumor cell drug sensitivity [151]. Elevated plasma levels of *miR-30b* and *miR-30c* were also associated with Erlotinib's inadequate response in EGFR mutant NSCLC patients [152].

Protein Tyrosine Phosphatase Non-Receptor Type 13 (PTPN13) belongs to the non-receptor tyrosine phosphatases that functions as a tumor suppressor in NSCLC [153]. PTPN13 dephosphorylates oncogenic proteins including TRIP6, HER2, and Insulin Receptor Substrate 1 (IRS-1) [153, 154]. It can also regulate the PI3K signaling via PIK3R2 dephosphorylation [155]. There was significant *miR-26a* up regulation in TKI-resistant NSCLC cells that promoted cell growth and TKI resistance via PTPN13 targeting. *MiR-26a* also activated Src by PTPN13 targeting that promoted EGFR signaling [156]. PI3K inhibitors significantly increase NSCLC cell susceptibility to drug-induced apoptosis. It has been shown that *miR-223* stimulated the IGF1R/PI3K/AKT signaling pathway and Erlotinib resistance in PC9/CD133+ cells [157]. Ras-related C3 botulinum toxin substrate 1 (Rac1) is a small GTPase from the Rho protein family that belongs to the Ras superfamily [158]. Rac1 is involved in various activities in cell differentiation, migration, proliferation, vesicle trafficking, and cytoskeletal dynamics [158, 159]. It has been reported that *miR-135a* stimulated cell proliferation, invasion, and Gefitinib resistance in NSCLC cells via Rac1 targeting and regulation of PI3K/AKT pathway [160].

**Sonic hedgehog (SHH), wingless/int (WNT), and nuclear factor-κB (NF-κB) signaling pathways**

The Hedgehog (Hh) pathway is a highly conserved signal transduction pathway that functions in cellular communications during embryonic development and is implicated in organogenesis, homeostasis, and regeneration [161]. Studies have indicated that aberrant activation of the Hh pathway induces cell proliferation and differentiation which culminates in tumorigenesis [162, 163]. Hyper-activation of Hh pathways is frequently observed in esophageal cancers [164], and it also promotes prostate cancer progression [165]. Gli-1 up-regulation was observed in residual esophageal tumors after chemoradiotherapy [166]. Hh signaling confers multidrug resistance through regulating the expression of ABC transporters family including Multidrug Resistance Protein 1 (MDR1) [167]. Drug efflux through the ABC transporters is considered the most important mechanisms of Multidrug Resistance (MDR) [168]. There was Small Nucleolar RNA Host Gene 14 (*SNHG14*) up-regulation in Gefitinib-resistant NSCLC tissues and cells. *SNHG14* increased ABCB1 protein expression by *miR-206-3p* sponging, leading to NSCLC Gefitinib resistance [169]. MiRNAs have a pivotal role in the regulation of the Sonic Hedgehog (SHH) pathway, which is essential in organogenesis and embryogenesis [170, 171]. It has been reported that under expression of *miR-506* activated the SHH pathway promoted EGFR-TKI, migration, and EMT process. The expression of *miR-506-3p* was significantly reduced in Erlotinib-resistant cells [172]. GLI1 is the main transcription factor of Hh signaling pathway [173, 174]. It has been observed that *miR-873* suppression significantly induced the proliferation of Gefitinib-treated PC9 cells, followed by GLI1 up-regulation. *MiR-873* suppression also enhanced angiogenesis and Gefitinib resistance in NSCLC cells [175].

WNT family is a group of secreted glycoproteins that functions as ligands binding to a Fzrizzled (Fz) family cell surface receptor to activate downstream signaling cascades [176, 177]. RTK and LRP-5/6 serve as co-receptors to facilitate the WNT ligand and Fz receptor interaction [178]. The signals are then transduced via canonical Wnt/β-catenin, non-canonical Wnt/calcium, and non-canonical Planar Cell Polarity (PCP) pathways [179]. Wnt pathway is involved in cellular differentiation, proliferation, maturation, and tumorigenesis [180–182]. Wnt signaling is involved in progression of various cancers including hepatocellular carcinoma, prostate, ovarian, pancreas, and breast cancers [183–187]. The Wnt pathway is responsible for the resistance of cancer cells to traditional chemotherapy and radiotherapy through regulating stemness and maintaining the CSCs [176]. LIM Homeobox (LHX) as the main subfamily of homeobox genes are involved in various malignancies [188]. LHX6 inhibits the Wnt/b-catenin signaling pathway to suppress the breast cancer cells proliferation and invasion [189]. It has a critical role in lung cancer via regulation apoptosis and cell cycle-related genes such as Tumor protein P53 (p53), B-Cell Lymphoma 2 (BCL-2), Cyclin D1 (CCND1), and Cyclin Dependent Kinase Inhibitor 1A (CDKN1A) [190]. There was *miR-214* up regulation in the plasma of NSCLC patients who acquire EGFR-TKI resistance. *MiR-214* promoted the Erlotinib resistance and the metastasis potential in HCC827 cells through LHX6 targeting [191].

The NF-κB encompasses a family of closely related transcription factors implicated in cell survival, immune responses, and cytokine production [192, 193]. The NF-κB activation is achieved through the non-canonical and canonical pathways [194]. In the canonical pathway, NF-κB is activated following targeted phosphorylation and subsequent degradation of IκB [195]. NF-κB signaling is involved in inflammatory and autoimmune disorders as well as cancers [194, 196, 197]. It has also been
reported that NF-kB exerts an anti-apoptotic role and promotes drug resistance in tumor cells [198–200]. In contrast, inhibition of NF-kB enhances cancer cell sensitivity to chemotherapeutic drugs via MDR1 down regulation [201]. Interleukin 1 Receptor Associated Kinase 1 (IRAK1) is serine/threonine kinase implicated in the NF-kB-regulated inflammatory response, antiapoptosis, and tumor development [202]. It has been reported that there was significant miR-146b-5p down regulation in EGFR TKI-resistant cells. MiR-146b-5p increased EGFR TKIs sensitivity by targeting IRAK1 [203].

TNF Superfamily Member 12 (TNFSF12) belongs to the Tumor Necrosis Factor (TNF) protein family expressed in a range of organs, immune cell types, and tumor cells, which activates caspase 8 and caspase 9 and cause extrinsic and intrinsic apoptosis cascades [204]. RHPN1-AS1 was down-regulated in Gefitinib-resistant NSCLC patients and cell lines. RHPN1-AS1 regulated Gefitinib resistance in NSCLC by targeting the miR-299-3p/TNFSF12 pathway. TNFSF12 also induced apoptosis in Gefitinib resistant tumor cells [205].

**Hippo and NOTCH signaling pathways**

The Hippo signaling is a structurally and functionally conserved pathway that has pivotal functions in regulation of organ size, cell proliferation, apoptosis, and tissue regeneration [206, 207]. Following the activation of the Hippo pathway, Mammalian Sterile 20-like kinase (MST1/2) is phosphorylated and promotes the activation of Large Tumor Suppressor (LATS1/2), which controls gene expression through phosphorylating and inhibiting the activity of the transcriptional co-activator proteins Yes-Associated Protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) [208, 209]. The Hippo pathway exerts tumor-suppressive functions and its mutations lead to the overgrowth of the affected cells [210]. Deregulation of the Hippo pathway also renders cancer cells resistant to chemotherapy [211]. Down-regulation of MST1 levels has been correlated to cisplatin resistance in prostate tumor cells [212]. On the other hand, YAP up-regulation was associated with resistance to taxane-based therapy in ovarian cancer [213]. There was miR-506-3p down regulation in NSCLC cells. MiR-506-3p reduced cell viability and apoptosis in PC-9GR cells after Gefitinib therapy. MiR-506-3p enhanced Gefitinib-induced Bcl-2 down regulation and Bax up regulation in PC 9GR cells. MiR-506-3p down regulation was associated with Gefitinib resistance via YAP1 regulation in NSCLC cells [214]. It has been shown that miR-630 down regulation may predict an adverse response to TKI treatment and a poor prognosis in lung adenocarcinoma. TKI resistance in EGFR-mutated lung cancer cells may be due to a feedback loop between miR-630-YAP1-ERK due to a Bad down-regulation caused by ERK signaling-induced phosphorylation. MiR-630 down regulation promoted ERK activation through YAP1 up regulation that resulted in TKI resistance. The miR-630/YAP1/ERK axis promotes TKI resistance in EGFR-mutated lung tumor cells [215].

Notch signaling is a cell–cell communication pathway involved in multiple cellular processes including embryonic development, proliferation, differentiation, EMT, migration, and apoptosis [216]. Following the interaction of the Notch receptors (NOTCH1-4) with a ligand–protein such as Delta-Like (DLL) and Jagged, proteolytic cleavage is induced and the intracellular domain is released which enters the nucleus to regulate the transcription of target genes [217, 218]. Aberrancies in this pathway have been correlated with a variety of developmental disorders of the heart, kidney, liver, and skeleton as well as malignancies [219, 220]. Moreover, Notch signaling is associated with drug resistance by promoting the formation of CSCs and mediating the EMT process [221, 222]. There were reduced levels of SNHG15 expression in Gefitinib-resistant LUAD cells due to NOTCH1 impairment. In Gefitinib-resistant cells, lack of SNHG15 inhibited cell proliferation, migration, and EMT processes while promoting cell death. NOTCH-1 promoted Gefitinib resistance through SNHG15/miR-451/ZEB1 axis [223]. There was miR-223 up-regulation in the Erlotinib-resistant HCC827 cells compared with parental. Increased expression of miR-223 stimulated the AKT and Notch signaling pathways in Erlotinib-resistant cells. MiR-223 may be a critical onco-miRNA that modulates NSCLC cell susceptibility to Erlotinib by regulating FBXW7. Erlotinib-resistant NSCLC patients may benefit from a new therapy that targets the Notch/miR-223/FBXW7 pathway [224].

**Conclusions**

TKIs are effective therapeutic modalities in the targeted therapy of various cancers; however they cause various side effects in cancer patients. Therefore, it is required to detect the lung cancer patients who are resistant toward the TKIs to manage the therapeutic methods and reduce side effects. Circulating miRNAs are tolerant toward different pH conditions and ambient temperature, showing their importance as efficient diagnostic and prognostic tumor markers. Since, miRNAs are involved in response to the anti-cancer drugs, drug response can be predicted by the miRNAs expression profiling. In the present review we have summarized specific miRNAs involved in the regulation of TKIs responses in lung tumor cells. It was observed that miRNAs affect the TKIs via regulation of various signaling pathways including NOTCH, WNT, PI3K/
AKT, Hippo, and JAK/STAT. All of these signaling pathways finally regulate the EMT through the specific transcription factors such as YAP, GLI1, ZEB1, and CSL. This review clarifies the molecular interactions between the miRNAs and signaling pathways during the TKIs response in lung tumor cells that paves the way of introducing a miRNA-based panel marker for detection of TKIs response in lung cancer patients. However, there is still a lack of miRNAs serum sample assessment in the majority of discussed reports. Therefore, in future studies it is necessary to evaluate the levels of miRNAs expressions in serum samples of lung cancer patients to introduce such factors as the non-invasive markers of TKIs response prediction.

Abbreviations
ABC: ATP-binding cassette; ABL1: Abelson tyrosine-protein kinase 1; AKT: Protein kinase B; BCL-2: B-cell lymphoma 2; BIM: Bcl2-interacting protein; CCND1: Cyclin D1; CDH1: Cadherin 1; CDKN1A: Cyclin dependent kinase inhibitor 1A; CSCs: Cancer stem cells; DMD: Delta-like; EGFR-TKI: EGFR tyrosine kinase inhibitors; EGFR: Epidermal growth factor receptor; EMT: Epithelial-to-mesenchymal transition; Elk-1: ETS-like-1 protein; Fz: Frizzled; GPR56: G-protein coupled receptor 56; HGF: Hepatocyte growth factor; Her: Hedgehog; IGF-1R: Insulin-like growth factor-1 receptor; IGFs: Insulin-like growth factors; IRAK1: Interleukin-1 receptor associated kinase 1; IRS-1: Insulin receptor substrate 1; JAK: Janus kinase; LATS1/2: Large tumor suppressor; LHx: LIM homeobox; MAPK: Mitogen-activated protein kinase; MAPKK: MAPK kinase; MAPKKK: MAPK kinase kinase; MDR1: Multidrug resistance protein 1; MDR: Multidrug resistance; MSCC: Mycobacterium species; NKX2:1: Homeobox; NSCLC: Non-small-cell lung cancer; PCP: Planar cell polarity; PELI3: Pellino E3 ubiquitin ligase; PI3K: Phosphatidylinositol 3-kinase; PTEN: Phosphatase and tensin homolog; PTPN13: Protein tyrosine phosphatase non-receptor type 13; PETN: Phosphatase and tensin homolog; PTPN13: Protein tyrosine phosphate non-receptor type 13; p53: Tumor protein P53; RTKs: Receptor tyrosine kinases; SCLC: Small-cell lung cancer; SHH: Sonic hedgehog; SNHG14: Small nucleolar RNA host gene 14; STAT: Signal transducer and activator of transcription; TAZ: Transcriptional co-activator with PDZ-binding motif; TIME: Tumor immune microenvironment; TKIs: Tyrosine kinase inhibitors; TRxs: Tyrosine kinase receptors; TGF: Transforming growth factor; TNF: Tumor necrosis factor; TNSF12: TNF superfamily member 12; WNT: Wingless/int; YAP: Yes-associated protein; ZEB: Zinc finger E-box-binding homeobox.

Acknowledgements
Not applicable.

Authors’ contributions
AM, ASZ, and Gr were involved in search strategy, drafting, and graphical illustrations. MM supervised the project and revised and edited the manuscript. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 2 Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Received: 17 December 2021 Accepted: 5 February 2022
Published online: 09 March 2022

References
1. Dubin S, Griffin D. Lung cancer in non-smokers. Mo Med. 2020;117(4):375–9.
2. Junior JR, Koenig-kam-Santos M, Cipriano FEG, Fabro AT, de Azevedo-Marques PM. Radiomics-based features for pattern recognition of lung cancer histopathology and metastases. Comput Methods Programs Biomed. 2018;159:23–30.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, NY). 2004;304(5676):1497–500.
5. Soria JC, Mok TS, Capuzzo F, Janne PA. EGFR-mutated oncogene-addicted non-small-cell lung cancer: current trends and future prospects. Cancer Treat Rev. 2011;38(5):416–30.
6. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005;23(14):3272–34.
7. Siveen KS, Prabhu KS, Achkar IW, Kuttikrishnan S, Shyam S, Khan AQ, et al. Role of non receptor tyrosine kinases in hematological malignancies and its targeting by natural products. Mol Cancer. 2018;17(1):31.
8. Prezeln N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endor Relat Cancer. 2001;8(1):11–31.
9. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23(11):2556–68.
10. Moghbeli M, Abbaszadegan MR, Farshchian M, Montazer M, Raeishasassi R, Abdollahi A, et al. Association of PYG02 and EGFR in esophageal squamous cell carcinoma. Med Oncol. 2013;30(2):516.
11. Hassanein SS, Ibrahim SA, Abdel-Mawgoud AL. Cell behavior of non-small cell lung cancer is at EGFR and microRNAs hands. Int J Mol Sci. 2021;22(2).
12. He M, Capelletti M, Nafa K, Yun CH, Arcila ME, Miller VA, et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res. 2012;18(6):1790–7.
13. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010;277(2):301–8.
14. Goeck E, Moulas AN, Studzinski GP. Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells. Crit Rev Clin Lab Sci. 2014;51(3):125–37.
15. Hahn O, Salgia R. Non-receptor tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med Chem. 2007;7(6):633–42.
16. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.
17. Ciuleanu T, Stelmakh L, Cicenas S, Millauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 trial. Lancet Oncol. 2012;13(3):300–8.
lungs: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(16):S21–9.
19. Wu YL, Kim JH, Park K, Zaatar A, Klingschmidt G, Ng C. Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study. Lung cancer. (Amsterdam, Netherlands). 2012;77(2):339–45.
20. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Correction to “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up” Ann Oncol. 2019;30(5):s863–70.
21. Harma N, Johnson D, Temin S, Baker Jr S, Brahmer J, Ellis PM, et al. Systemic therapy for stage IV non-small cell lung cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35(30):s3484–515.
22. Gainor JF, Shaw AT. Emerging paradigms in the development of maintenance EGFR TKI targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38.
23. Engels BM, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene. 2006;25(46):6163–9.
24. Zangouei AS, Moghbeli M. MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells. Cancer Cell Int. 2021;21(1):213.
25. Zangouei AS, Moghbeli M. MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells. Genes Environ. 2021;43(1):21.
26. Bao L, Hazari S, Mehra S, Kauralsial D, Moroz K, Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol. 2012;180(6):2490–503.
27. Kutanz KR, Yurchenko OV, Beland FA, Chekkhun VF, Pogribny IP. MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics. 2011;2(2):171–85.
28. Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz J, et al. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer. 2011;18(1):85–95.
29. Shi L, Zhang S, Wu H, Zhang L, Dai X, Hu J, et al. miR-200c increases the radiosensitivity of non-small-cell lung cancer cell line A549 by targeting VEGF-VEGFR2 pathway. PLoS ONE. 2013;8(10):e79344.
30. Zhen Q, Liu J, Wang J, Chu W, et al. MicroRNA-200a targets EGFR and c-met to inhibit migration, invasion, and gefitinib resistance in non-small-cell lung cancer. Cancer Res. 2015;16(9):e447–59.
31. Zhou YM, Liu J, Sun W. MiR-130a overcomes gefitinib resistance and strategies. Am J Cancer Res. 2014;4(5):411–5.
32. Lin Y, Wang X, Jin H. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res. 2014;4(5):411–5.
33. Yarden Y, Slwowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.
34. Jones RB, Gordus A, Krafl JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature. 2006;439(7073):168–74.
35. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.
36. Mitsudomi T, Morita S, Yatabe Y, Nogaro S, Okamoto I, Tsutsumi J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WITOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8.
37. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.
38. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8.
39. Harma N, Johnson D, Temin S, Baker Jr S, Brahmer J, Ellis PM, et al. Systemic therapy for stage IV non-small cell lung cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35(30):3484–515.
40. Gainor JF, Shaw AT. Emerging paradigms in the development of maintenance EGFR TKI targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38.
41. Engels BM, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene. 2006;25(46):6163–9.
42. Zangouei AS, Alimandari M, Moghbeli M. MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells. Cancer Cell Int. 2021;21(1):213.
43. Zangouei AS, Moghbeli M. MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells. Genes Environ. 2021;43(1):21.
44. Bao L, Hazari S, Mehra S, Kauralsial D, Moroz K, Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol. 2012;180(6):2490–503.
45. Kutanz KR, Yurchenko OV, Beland FA, Chekkhun VF, Pogribny IP. MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics. 2011;2(2):171–85.
46. Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz J, et al. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer. 2011;18(1):85–95.
47. Lin Y, Wang X, Jin H. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res. 2014;4(5):411–5.
48. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.
49. Jones RB, Gordus A, Krafl JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature. 2006;439(7073):168–74.
50. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.
51. Mitsudomi T, Morita S, Yatabe Y, Nogaro S, Okamoto I, Tsutsumi J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WITOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8.
52. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.
53. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8.
54. Harma N, Johnson D, Temin S, Baker Jr S, Brahmer J, Ellis PM, et al. Systemic therapy for stage IV non-small cell lung cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35(30):3484–515.
55. Lin Y, Wang X, Jin H. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res. 2014;4(5):411–5.
56. Yarden Y, Slwowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.
57. Jones RB, Gordus A, Krafl JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature. 2006;439(7073):168–74.
by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994;77(2):261–71.

62. Sipeki S, Bander E, Buday L, Farkas G, Bácsy E, Ways DK, et al. Phosphati-
63. Cao X, Lai S, Hu F, Li G, Wang G, Luo X, et al. miR-19a contributes to
gfp-19a contributes to
gfp-19a contributes to
gfp-19a contributes to
gfp-19a contributes to
gfp-19a contributes to
66. Chen Y, Zhang F, Tsai Y, Yang X, Yang L, Duan S, et al. IL-6 signaling
67. Trumpp A, Wiestler OD. Mechanisms of disease: cancer stem cells—
68. Yao Y, Dou C, Lu Z, Zheng X, Liu Q. MACC1 suppresses cell apoptosis in
69. Trovato M, Torre ML, Ragonese M, Simone A, Scarfì R, Barresi V, et al.
70. Jiang J, Feng X, Zhou W, Wu Y, Yang Y. MiR-128 reverses the gefitinib
71. Iyer G, Price J, Bourgeois S, Armstrong E, Huang S, Harari PM. Insulin-
72. Yang L, Chen G, Mohanty S, Scott G, Fazal F, Rahman A, et al. GPR56
73. Kuhnert F, Mancuso MR, Shamloo A, Wang HT, Choksi V, Florek M, et al.
74. Yang L, Chen G, Mohanty S, Scott G, Fazal F, Rahman A, et al. GPR56
75. Zhao FY, Han J, Chen XW, Wang J, Wang XD, Sun JG, et al. miR-223 enhances
76. Lei T, Zhang L, Song Y, Wang B, Shen Y, Zhang N, et al. miR-1262 tradi-
77. Zhang N, Li Y, Zheng Y, Zhang L, Pan Y, Ju J, et al. miR-608 and miR-4513
78. Yang L, Chen G, Mohanty S, Scott G, Fazal F, Rahman A, et al. GPR56
79. Cullen M, Elzarrar M, Seaman S, Zudaire E, Stevens J, Yang MY, et al.
80. Ciardiello F, Bianco R, Caputo R, Caputo R, Darnino V, Troiani T, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor
81. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR
82. Gao Y, Fan X, Li W, Ping W, Deng Y, Fu X. miR-138-5p reverses gefitinib
83. Sun Y, Liu WZ, Liu T, Feng X, Yang N, Zhou HF. Signaling pathway of
84. Morrison DK. MAP kinase pathways. Cold Spring Harb Perspect Biol.
85. Souza JA, Rossa C Jr, Garlet GP, Quezada AV, Civelli JA. Modulation of
86. Lawrence MC, Jivan A, Shao C, Duan L, Zaganjor E, et al. The
87. Lawrence MC, Jivan A, Shao C, Duan L, Zaganjor E, et al. The
88. Guo X, Ma N, Wang J, Song J, Bu X, Cheng Y, et al. Increased p38-MAPK
89. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB,
90. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitorAZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139–46.
91. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, et al. (V600E)BRAF
92. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358–62.
93. Bai E, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, et al. STAT3 medi-
94. Chait Y, Orlando MF, Buday L, Farkas G, Sipeki S, Bander E, et al. Signaling pathways and angiogenesis during melanoma progression. Autophagy. 2014;10(11):1937–52.
95. Giegerich AK, Kuchler L, Sha LK, Knape T, Heide H, Witting I, et al. Autophagy-dependent PEL1 degradation inhibits proinflammatory IL1B expression. Autophagy. 2014;10(11):1937–52.
96. Yang S, Wang B, Humphries F, Hogun AE, O'Shea D, Moynagh PN. The E3 ubiquitin ligase Pellino3 protects against obesity-induced inflammation and insulin resistance. Immunity. 2014;41(6):973–87.
97. Zinko R, Hipskind RA, Pingoud V, Nordheim A, c-fos transcriptional activa-
98. Sirvent A, Benistant C, Roche S. Cytoplasmic signalling by the c-Abi tyrosine kinase in normal and cancer cells. Biol Cell. 2008;110(11):617–31.
99. Sirvat Khan, D. D. P., Khan, M. A., Khan, R. A., et al. Oncogenic activation of c-Abi in small-cell lung cancer cells lacking FUS1 expression: inhibition of c-Abi by the tumor suppressor gene product Fus1. Oncogene. 2007;26(49):6989–96.
100. Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS, Hwang SG, et al. Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abi-ERK signaling pathway in human liver cancers. Oncogene. 2013;32(41):4873–82.
104. Renshaw MW, Lewis JM, Schwartz MA. The c-Abl tyrosine kinase contributes to the transient activation of MAP kinase in cells plated on fibronectin. Oncogene. 2000;19(28):3216–9.
105. Sun Y, Chen C, Zhang P, Xie H, Hou L, Hui Z, et al. Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Rac/ERK pathway. Sci Rep. 2014;4:e6527.
106. Puig T, Aguilar H, Cufí S, Oliveras G, Turrado C, Ortega-Gutiérrez S, et al. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. BCR. 2011;13(3):R131.
107. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010;101(2):293–9.
108. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA Jr, et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007;6(6):1683–91.
109. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res. 2005;11(24 Pt 1):8686–90.
110. Li J, Li X, Ren S, Chen X, Zhang Y, Zhou F, et al. miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget. 2014;5(17):7902–16.
111. Zhou G, Zhang F, Guo Y, Huang J, Xie Y, Yue S, et al. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibits cell migration via targeting ZEB1. Biomed Pharmacother. 2017;85:113–9.
112. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;67(1):1-8.
113. Gutiérrez-Hoya A, Soto-Cruz I. Role of the JAK/STAT pathway in cervical cancer: its relationship with HPV E6/E7 oncoproteins. Cells. 2020;9(12):2734.
114. Sel R, Shiken K, Tomida S, Okayasu K, Suzawa K, Hashida S, et al. Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features. Sci Rep. 2017;7:40847.
115. Yue J, Lv D, Wang C, Li L, Zhao Q, Chen H, et al. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3. Oncogene. 2018;37(31):4300–12.
116. Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;67(1):1-8.
117. Li J, Li X, Ren S, Chen X, Zhang Y, Zhou F, et al. miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget. 2014;5(17):7902–16.
118. Tuyl J, Zuliani T, Wolowicz K, Kuranda K, Prochazkova J, Andreix J, et al. The PI3K/AKT signaling pathway controls the quiescence of the low-Rhodamine123-retention cell compartment enriched for melano-noma stem cell activity. Stem Cells. 2013;31(4):641–51.
119. Okeda L, Gao J, Hooten KG, Wang E, Thonhoff JR, Dunn TJ, et al. Critical role of PI3K/Akt/GSK3β in motoneuron specification from human neural stem cells in response to FGF2 and EGF. PLoS ONE. 2011;6(8):e23414.
120. Piettenello D, O'Neill A, Schaffer DV, PI3K/Akt and CREB regulate adult hippocampal progenitor proliferation and differentiation. Dev Neurobiol. 2007;67(10):1548–61.
121. Sun Y, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;67(1):1-8.
122. Qin Y, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;67(1):1-8.
123. Qin Y, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;67(1):1-8.
124. Qin Y, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;67(1):1-8.
125. Qin Y, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;67(1):1-8.
147. Zhou J, Wang J, Zeng Y, Zhang X, Hu Q, Zheng J, et al. Implication of epithelial-mesenchymal transition in IGF-1R-induced resistance to EGF-R-TKIs in advanced non-small cell lung cancer. Oncotarget. 2015;6(42):44332–45.

148. Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, et al. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol (Dordr). 2013;36(4):277–88.

149. Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, et al. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Lung Cancer (Amsterdam, Netherlands). 2015;87(3):311–7.

150. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Can Res. 2006;66(20):10100–11.

151. Meng F, Wang F, Wang L, Wong SC, Cho WC, Chan LW. MiR-30a-5p overexpression may overcome EGFR-inhibitor resistance through regulating PI3K/AKT signaling pathway in non-small lung cancer cell lines. PI3K. 2016;18:197.

152. Hojbjerg JA, Ebert EBF, Clement MS, Winther-Larsen A, Meldgaard P, Scrima M, De Marco C, De Vita F, Fabiani F, Franco R, Pirozzi G, et al. The PTEN phosphatase and tensin homolog (PTEN) gene is a tumor suppressor gene in non-small cell lung cancer. Am J Pathol. 2012;180(3):1202–14.

153. Srinra M, De Marco C, De Vita F, Fabiani F, Franco R, Pirozzi G, et al. The non-receptor-type tyrosine phosphatase PTPN13 is a tumor suppressor gene in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2019;153:92–6.

154. Freiss G, Chalbos D. PTPN13/PTPL1: an important regulator of tumor cell proliferation and induction of survivin expression counteract the antitumor action of erlotinib. Can Res. 2006;66(20):10100–11.

155. Xu S, Wang T, Yang Z, Li Y, Li W, Wang T, et al. miR-26a desensitizes non-small cell lung cancer to gefitinib by sponging miR-206-3p. Biomed Pharmacother. 2019;116:108995.

156. Han J, Zhao F, Zhang J, Zhu H, Ma H, Li X, et al. miR-223 reverses the resistance of erlotinib. Can Res. 2006;66(20):10100–11.

157. Sylow L, Jensen TE, Kleinert M, Mouatt JR, Maarbjerg SJ, Jeppesen J, Davidson I, Sorensen B. Circulating miR-30b and miR-30c predict erlotinib response and outcome in non-small cell lung cancer patients harboring activating EGFR mutations. Lung Cancer (Amsterdam, Netherlands). 2013;80(2):277–88.

158. Haque I, Kawsar HI, Motes H, Sharma M, Banerjee S, Banerjee SK, et al. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMR-regulating miRNAs. J Hematol Oncol. 2013;6(1):77.

159. Pietrobono S, Santini R, Gagliardi S, Dappporto F, Colecchia D, Chiarello M, et al. Targeted inhibition of Hedgehog-Gli signaling by novel acylguanidine derivatives inhibits melanoma cell growth by inducing replication stress and mitotic catastrophe. Cell Death Dis. 2018;9(2):142.

160. Zhang T, Wang N. miR-135a confers resistance to gefitinib in non-small cell lung cancer. Oncol Res. 2018;26(3):5674–9.

161. Fletcher JI, Williams RT, Henderson MJ, Norris MD, Haber M. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updat. 2016;26:1–9.

162. Wu K, Li J, Qiy, Zhang C, Zhu D, Liu D, et al. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p. Biomed Pharmacother. 2019;116:108995.

163. Kuchay S, Duan S, Schenkein E, Peschiaroli A, Saraf A, Florens L, et al. The PTEN regulatory subunit controls the PI(3)K signalling cascade. Nat Cell Biol. 2019;21(9):1145–54.

164. Pirollo Te, Kühl M. An updated overview on Wnt signaling pathways: a missing link in cancer. Interdiscip Rev Syst Biol Med. 2016;8(3):227–41.

165. Abbaszadegan MR, Riahi A, Forghaniard MM, Moghbeli M. WNT and NOTCH signaling pathways as mediators of drug resistance and contributors to cancer cell growth. Anticancer Agents Med Chem. 2011;11(1):78–88.

166. Haque I, He C, Hu X. LIM homeobox transcription factors, a novel subfamily which plays an important role in cancer (review). Oncol Rep. 2014;31(5):1975–85.

167. Wang X, He C, Hu X. LIM homeobox transcription factors, a novel subfamily which plays an important role in cancer (review). Oncol Rep. 2014;31(5):1975–85.

168. Liu WB, Jiang X, Han F, Li Y, Chen HQ, Liu Y, et al. LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancer. Cell Death Disease. 2013;4:e882.

169. Liao J, Lin J, Lin D, Zou C, Kurata J, Lin R, et al. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression. Sci Rep. 2017;7(1):781.

170. Dolcet X, Llobet D, Pallares J, Matias-Guixé X. NF-kB in inflammation. Signal Transduct Target Ther. 2017;2:17023.

171. Miller JR. The Wnts. Genome Biol. 2002;3(1):Reviews3001.

172. Routledge D, Scholpp S. Mechanisms of intercellular Wnt transport. Development. 2018;145(10).

173. Abbaszadegan MR, Riahi A, Forghaniard MM, Moghbeli M. WNT and NOTCH signaling pathways as mediators of drug resistance and contributors to cancer cell growth. Anticancer Agents Med Chem. 2011;11(1):78–88.

174. Groves MR. The Wnt pathway in advanced prostate cancer. Mol Cancer. 2015;14(10).

175. Chesire DR, Isaacs WB. Beta-catenin signaling in prostate cancer: an updated overview. Anticancer Agents Med Chem. 2011;11(1):78–88.

176. Groves MR. The Wnt pathway in advanced prostate cancer. Mol Cancer. 2015;14(10).

177. Miller JR. The Wnts. Genome Biol. 2002;3(1):Reviews3001.

178. Groves MR. The Wnt pathway in advanced prostate cancer. Mol Cancer. 2015;14(10).

179. Routledge D, Scholpp S. Mechanisms of intercellular Wnt transport. Development. 2019;146(10).

180. Abbaszadegan MR, Riahi A, Forghaniard MM, Moghbeli M. WNT and NOTCH signaling pathways as mediators of drug resistance and contributors to cancer cell growth. Anticancer Agents Med Chem. 2011;11(1):78–88.
Baldwin AS Jr. The NF-κappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–83.

Wong ET, Tergaonkar V. Roles of NF-kappaB in health and disease: mechanisms and therapeutic potential. Clin Sci (Lond). 2009;116(6):451–65.

Baker RG, Hayden MG, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab. 2011;13(1):11–22.

Wu M, Lee H, Bellas RE, Schauer SL, Arusura M, Katz D, et al. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. J Exp Med. 1996;175(7):799–809.

Barlow RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, et al. Constitutive nuclear factor-kappaB/RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J Clin Invest. 1997;100(12):2961–9.

Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest. 1997;100(12):2952–60.

Bentires-Alj M, Barbu V, Fillet M, Charont A, Relic B, Jacobs N, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003;22(1):90–7.

Inkner A, Ashkenazi A. TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. J Biol Chem. 2011;286(24):21546–54.

Li X, Zhang X, Yang C, Cui S, Shen Q, Xu S. The IncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting the IRAK1/NF-κB pathway. Molecular therapy Nucleic acids. 2020;22:471–83.

Han Y. Analysis of the role of the Hippo pathway in cancer. J Transl Med. 2019;17(1):116.

Misra JR, Irvine KD. The hippo signaling network and its biological functions. Annu Rev Genet. 2018;52:65–87.

Xiao JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014;15(6):642–56.

Zhao Y, Yang X. The Hippo pathway in chemotherapeutic drug resistance. Int J Cancer. 2015;137(2):2767–73.

Ren A, Yan G, You B, Sun J. Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res. 2008;68(7):2266–74.

Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, et al. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res. 2014;34(2):811–7.

Zhu J, Tao L, Jin L. MicroRNA-506-3p reverses gefitinib resistance in non-small cell lung cancer by targeting Yes-associated protein 1. Mol Med Rep. 2019;19(2):1331–9.

Wu DW, Wang YC, Wang L, Chen CY, Lee H. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop. Theranostics. 2018;8(5):1256–69.

Sato G, Zhao G, Iliyan MX. An overview of notch signaling in adult tissue renewal and maintenance. Curr Alzheimer Res. 2012;9(2):227–40.

Kopan R. Notch signaling. Cold Spring Harb Perspect Biol. 2012;4(10).

Hori K, Sen A, Artavanis-Tsakonas S. Notch signaling at a glance. J Cell Sci. 2013;126(Pt 1):2135–40.

Harper JA, Yuan JS, Tan JB, Visan I, Guidos CJ. Notch signaling in development and disease. Clin Genet. 2003;64(6):461–72.

Penton AL, Leonard LD, Spinner NB. Notch signaling in human development and disease. Semin Cell Dev Biol. 2012;23(4):450–7.

Zhang J, Zheng G, Zhou L, Li P, Yun M, Shi Q, et al. Notch signaling induces epithelial-mesenchymal transition to promote metastasis in oral squamous cell carcinoma. Int J Mol Med. 2018;42(4):2276–84.

Wang J, Sullenger BA, Rich JN. Notch signaling in cancer stem cells. Adv Exp Med Biol. 2012;727:174–85.

Huang J, Pan B, Xia G, Zhu J, Li C, Feng J. LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR1. Cell Death Dis. 2020;11(7):525.

Zhang H, Chen F, He Y, Yi L, Ge C, Shi X, et al. Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway. Biosci Rep. 2017;37(3).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.